A Phase 2 interventional study of ABT-981 and Placebo in Knee Osteoarthritis and Medial Compartment Knee Osteoarthritis, sponsored by AbbVie. Completed. Open to participants aged 35 Years to 74 Years. Per ClinicalTrials.gov, last updated 2019-08-28.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 2a, multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety, tolerability, efficacy and pharmacokinetic/pharmacodynamic effect of ABT-981 in patients with symptomatic, radiographic, and inflammatory knee osteoarthritis.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
This study's enrollment of 350 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Browse Osteoarthritis, Knee studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
Biological: ABT-981
100 mg ABT-981 SC E2W
Biological: ABT-981
200 mg ABT-981 SC E2W
Biological: ABT-981
Placebo
Other: Placebo
Also known as: Lutikizumab
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 16
Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26
Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.
Time frame: Baseline, Week 26
Change From Baseline in Effusion Volume of the Index Knee at Week 26
Time frame: Baseline, Week 26
Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26
Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), \< 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or \> 66% of maximum estimated distention (3).
Time frame: Baseline, Week 26
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 16
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 52
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 26
Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
Time frame: Baseline, Week 52
Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
Time frame: Baseline, Week 26
Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
Time frame: Baseline, Week 52
Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Time frame: Baseline, Week 16
Change From Baseline in Index Knee ICOAP Scores at Week 26
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Time frame: Baseline, Week 26
Change From Baseline in Index Knee ICOAP Scores at Week 52
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
Time frame: Baseline, Week 52
Change From Baseline In Index Knee Pain Intensity at Week 16
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Time frame: Baseline, Week 16
Change From Baseline In Index Knee Pain Intensity at Week 26
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Time frame: Baseline, Week 26
Change From Baseline In Index Knee Pain Intensity at Week 52
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
Time frame: Baseline, Week 52
Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Time frame: Baseline, Week 16
Change From Baseline in PGA of Arthritis of the Index Knee at Week 26
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Time frame: Baseline, Week 26
Change From Baseline in PGA of Arthritis of the Index Knee at Week 52
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
Time frame: Baseline, Week 52
Change From Baseline in Cartilage Volume of the Index Knee at Week 26
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Time frame: Baseline, Week 26
Change From Baseline in Cartilage Volume of the Index Knee at Week 52
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Time frame: Baseline, Week 52
Change From Baseline in Cartilage Thickness of the Index Knee at Week 26
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Time frame: Baseline, Week 26
Change From Baseline in Cartilage Thickness of the Index Knee at Week 52
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
Time frame: Baseline, Week 52
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16
Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Time frame: Week 16
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26
Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Time frame: Week 26
Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52
Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
Time frame: Week 52
| Milestone | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Started | 85 | 89 | 87 | 89 |
| Completed | 60 | 70 | 65 | 64 |
| Not completed | 25 | 19 | 22 | 25 |
| Withdrew: Did not receive study drug | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 8 | 4 | 4 | 12 |
| Withdrew: Lack of efficacy | 3 | 6 | 3 | 2 |
| Withdrew: Other | 6 | 2 | 4 | 4 |
| Withdrew: Withdrawal by subject | 8 | 3 | 7 | 4 |
| Withdrew: Lost to follow-up | 0 | 4 | 2 | 2 |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16 | -8.9 (-10.96 to -6.90) | -9.2 (-11.23 to -7.23) | -11.8 (-13.84 to -9.75) | -10.1 (-12.10 to -8.10) |
Change in synovitis of the index knee was evaluated using quantitative magnetic resonance imaging (MRI) measurements. MRI quantitative synovitis of the index knee was defined by mean synovial membrane thickness.
| mm | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26 | -0.05 (-0.107 to 0.011) | 0.01 (-0.045 to 0.068) | -0.08 (-0.134 to -0.016) | 0.01 (-0.047 to 0.067) |
| mL | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Effusion Volume of the Index Knee at Week 26 | 0.03 (-2.498 to 2.562) | 0.26 (-2.113 to 2.624) | -1.04 (-3.421 to 1.347) | -1.49 (-3.868 to 0.898) |
Semi-quantitative synovitis/effusion volume WORMS scores were scored as normal (0), \< 33% of maximum estimated distention (1), 33% - 66% of maximum estimated distention (2), or \> 66% of maximum estimated distention (3).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26 | 0.07 (-0.057 to 0.193) | -0.01 (-0.130 to 0.113) | -0.08 (-0.205 to 0.043) | -0.07 (-0.196 to 0.048) |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16 | -28.7 (-35.30 to -22.15) | -29.8 (-36.27 to -23.32) | -36.3 (-42.90 to -29.69) | -32.1 (-38.64 to -25.63) |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26 | -29.7 (-36.61 to -22.75) | -31.8 (-38.62 to -24.98) | -38.9 (-45.83 to -31.92) | -36.9 (-43.71 to -30.00) |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) NRS. The WOMAC physical function subscale score was 0 (normal) to 170 (least physical function). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52 | -32.9 (-40.66 to -25.12) | -36.1 (-43.76 to -28.46) | -38.7 (-46.52 to -30.92) | -39.7 (-47.37 to -32.00) |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26 | -9.2 (-11.29 to -7.07) | -9.8 (-11.90 to -7.75) | -11.9 (-13.99 to -9.76) | -11.6 (-13.65 to -9.51) |
The WOMAC was developed to assess pain, stiffness, and physical function in subjects with hip and/or knee osteoarthritis. The WOMAC consists of 24 items divided into 3 subscales: Pain (5 items); Stiffness (2 items); and Physical Function (17 items). Each item is rated on an 11-point (0 to 10) numerical rating scale (NRS). The pain sub-score has a range of 0 (no pain) to 50 (maximum pain). A negative change from baseline indicates improvement.
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52 | -10.0 (-12.24 to -7.68) | -11.0 (-13.29 to -8.80) | -12.1 (-14.42 to -9.84) | -12.2 (-14.49 to -10.0) |
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26 | 0.1 (-0.24 to 0.43) | 0.3 (0.01 to 0.65) | -0.0 (-0.37 to 0.29) | 0.1 (-0.22 to 0.43) |
BMLs in 15 regions were measured with MRI, and graded as 0 (normal), 1 (mild; \< 25% of region), 2 (moderate; 25% - 50% of region), or 3 (severe; \> 50% of region). The global total BML score was the sum of the 15 component scores, and ranged from 0 (normal) to 45 (severe).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52 | 0.1 (-0.34 to 0.48) | 0.2 (-0.16 to 0.60) | 0.1 (-0.30 to 0.48) | 0.0 (-0.36 to 0.39) |
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Intermittent Pain | -20.2 (-24.32 to -16.08) | -19.5 (-23.40 to -15.58) | -21.3 (-25.40 to -17.26) | -18.8 (-22.92 to -14.71) |
| Constant Pain | -18.6 (-22.88 to -14.33) | -17.7 (-21.73 to -13.62) | -24.2 (-28.39 to -19.94) | -20.0 (-24.24 to -15.72) |
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Intermittent Pain | -18.7 (-23.21 to -14.21) | -19.7 (-23.99 to -15.42) | -21.3 (-25.66 to -16.98) | -21.7 (-26.11 to -17.38) |
| Constant Pain | -19.6 (-24.22 to -14.96) | -18.8 (-23.26 to -14.42) | -21.6 (-26.05 to -17.08) | -22.1 (-26.61 to -17.61) |
The ICOAP is a multidimensional osteoarthritis-specific measure designed to comprehensively evaluate the pain experience in patients with hip or knee osteoarthritis. The ICOAP includes 11 items (5 constant pain items; 6 intermittent pain items). Each item is rated on a 0 to 4 point scale with a 7-day recall period. The raw maximum intermittent pain score ranges from 0 to 24, transformed to a reported scale of 0 (no pain) to 100 (worst pain). The raw maximum constant pain score ranges from 0 to 20, transformed to a reported scale of 0 (no pain) to 100 (worst pain).
| score on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Intermittent Pain | -23.2 (-28.51 to -17.83) | -25.4 (-30.21 to -20.51) | -23.6 (-28.53 to -18.64) | -27.2 (-32.19 to -22.14) |
| Constant Pain | -20.6 (-25.93 to -15.21) | -21.8 (-26.70 to -16.94) | -25.2 (-30.14 to -20.17) | -29.7 (-34.78 to -24.66) |
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| 7-Day Recall Period | -2.4 (-2.86 to -1.97) | -2.4 (-2.79 to -1.95) | -2.7 (-3.09 to -2.22) | -2.1 (-2.55 to -1.67) |
| Activity Pain | -2.3 (-2.85 to -1.82) | -2.4 (-2.85 to -1.87) | -2.7 (-3.19 to -2.17) | -2.1 (-2.59 to -1.56) |
| Performance Pain (Before) | -2.4 (-2.82 to -1.89) | -2.1 (-2.58 to -1.70) | -2.5 (-2.97 to -2.06) | -2.1 (-2.52 to -1.60) |
| Performance Pain (After) | -2.6 (-3.07 to -2.11) | -2.4 (-2.90 to -2.00) | -2.7 (-3.16 to -2.22) | -2.3 (-2.77 to -1.82) |
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| 7-Day Recall Period | -2.2 (-2.76 to -1.73) | -2.4 (-2.89 to -1.91) | -2.8 (-3.29 to -2.31) | -2.5 (-2.98 to -1.99) |
| Activity Pain | -2.5 (-3.07 to -1.91) | -2.5 (-3.10 to -1.99) | -2.8 (-3.37 to -2.25) | -2.5 (-3.10 to -1.97) |
| Performance Pain (Before) | -2.2 (-2.72 to -1.70) | -2.2 (-2.68 to -1.71) | -2.6 (-3.13 to -2.16) | -2.7 (-3.15 to -2.17) |
| Performance Pain (After) | -2.5 (-3.01 to -1.98) | -2.4 (-2.90 to -1.92) | -3.0 (-3.53 to -2.54) | -2.6 (-3.13 to -2.13) |
The index knee pain intensity was assessed in 3 different ways using an 11 -point NRS (0 to 10 points representing 'no pain' to 'worst possible pain'). Subjects were asked to enter: 1) average pain intensity during the past week (7-day recall period); 2) the worst pain during activity over the past 24 hours; 3) pain intensity before and after a 40 meter walk (performance pain, before and after). The 40 meter fast paced walk test is a test of short distance walking activity, walking speed over short distances and changing direction during walking. Individuals taking the test should walk as quickly but as safely as possible, without running, along a walkway and then turn around, and repeat again for a total distance of 40 m (132 feet). The total time taken to walk the 40 meters is recorded.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| 7-Day Recall Period | -2.9 (-3.51 to -2.35) | -2.9 (-3.45 to -2.39) | -2.9 (-3.43 to -2.35) | -3.1 (-3.65 to -2.56) |
| Activity Pain | -2.8 (-3.48 to -2.16) | -3.0 (-3.64 to -2.43) | -3.2 (-3.77 to -2.55) | -3.0 (-3.65 to -2.40) |
| Performance Pain (Before) | -2.6 (-3.14 to -2.03) | -2.7 (-3.24 to -2.23) | -3.0 (-3.51 to -2.49) | -2.9 (-3.46 to -2.41) |
| Performance Pain (After) | -2.9 (-3.47 to -2.33) | -3.0 (-3.53 to -2.50) | -3.4 (-3.90 to -2.86) | -3.2 (-3.69 to -2.62) |
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16 | -2.5 (-2.94 to -2.01) | -2.4 (-2.80 to -1.92) | -2.9 (-3.34 to -2.42) | -2.6 (-3.08 to -2.15) |
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in PGA of Arthritis of the Index Knee at Week 26 | -2.4 (-2.96 to -1.91) | -2.4 (-2.94 to -1.94) | -3.0 (-3.48 to -2.47) | -2.7 (-3.18 to -2.16) |
The PGA is a single item for evaluating overall osteoarthritis disease activity. PGA is assessed using an 11-point NRS of 0 to 10 points (representing best to worst disease status, respectively), with a 7-day recall period.
| units on a scale | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Change From Baseline in PGA of Arthritis of the Index Knee at Week 52 | -3.0 (-3.62 to -2.44) | -2.9 (-3.48 to -2.41) | -3.2 (-3.71 to -2.62) | -3.5 (-4.01 to -2.89) |
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
| mm^3 | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Global Knee | -326.0 (-400.83 to -251.13) | -325.5 (-397.10 to -253.83) | -322.4 (-400.20 to -244.61) | -359.0 (-429.72 to -288.35) |
| Medial Central Condyle + Plateau | -59.1 (-83.12 to -35.10) | -54.9 (-77.83 to -31.90) | -50.1 (-75.13 to -25.07) | -57.5 (-80.12 to -34.88) |
| Medial Condyle + Plateau | -128.6 (-166.76 to -90.50) | -126.5 (-163.03 to -90.02) | -124.5 (-164.13 to -84.86) | -114.9 (-150.86 to -78.90) |
Cartilage volume of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
| mm^3 | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Global Knee | -557.0 (-659.86 to -454.10) | -598.7 (-694.66 to -502.76) | -554.3 (-654.92 to -453.60) | -583.1 (-678.88 to -487.23) |
| Medial Central Condyle + Plateau | -101.2 (-134.56 to -67.79) | -126.3 (-157.5 to -95.09) | -90.1 (-122.89 to -57.29) | -113.0 (-144.08 to -81.84) |
| Medial Condyle + Plateau | -214.7 (-273.77 to -155.64) | -255.0 (-310.03 to -199.97) | -190.3 (-248.05 to -132.51) | -242.8 (-297.71 to -187.86) |
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
| mm | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Global Knee | -0.047 (-0.058 to -0.036) | -0.047 (-0.058 to -0.037) | -0.048 (-0.059 to -0.037) | -0.052 (-0.062 to -0.041) |
| Medial Central Condyle + Plateau | -0.085 (-0.122 to -0.048) | -0.077 (-0.113 to -0.042) | -0.074 (-0.113 to -0.036) | -0.076 (-0.111 to -0.041) |
| Medial Condyle + Plateau | -0.046 (-0.060 to -0.031) | -0.045 (-0.059 to -0.031) | -0.047 (-0.062 to -0.032) | -0.044 (-0.058 to -0.031) |
Cartilage thickness of the global knee, the medial central condyle + plateau, and the medial condyle + plateau was measured using MRI.
| mm | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Global Knee | -0.081 (-0.095 to -0.066) | -0.085 (-0.099 to -0.072) | -0.081 (-0.095 to -0.067) | -0.083 (-0.097 to -0.070) |
| Medial Central Condyle + Plateau | -0.136 (-0.187 to -0.084) | -0.176 (-0.224 to -0.127) | -0.113 (-0.163 to -0.062) | -0.141 (-0.190 to -0.093) |
| Medial Condyle + Plateau | -0.084 (-0.106 to -0.063) | -0.096 (-0.117 to -0.076) | -0.073 (-0.094 to -0.052) | -0.087 (-0.107 to -0.067) |
Percentage of participants classified as OMERACT-OARSI responders at Week 16. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
| percentage of participants | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16 | 60.0 (49.6 to 70.4) | 67.0 (57.2 to 76.9) | 72.6 (63.1 to 82.2) | 65.5 (55.5 to 75.5) |
Percentage of participants classified as OMERACT-OARSI responders at Week 26. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
| percentage of participants | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26 | 62.4 (52.1 to 72.7) | 64.8 (54.8 to 74.8) | 66.7 (56.6 to 76.7) | 72.7 (63.4 to 82.0) |
Percentage of participants classified as OMERACT-OARSI responders at Week 52. A subject was considered an OMERACT-OARSI responder if any of the following 3 criteria were met: 1. WOMAC Pain (in 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 2. WOMAC Function (in normalized 0 - 100 scale) improvement ≥ 50% and absolute reduction ≥ 20 as compared to the baseline; or 3. At least 2 of the following 3 are met: WOMAC Pain improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; WOMAC Function improvement ≥ 20% and absolute reduction (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline; PGA improvement ≥ 20% and absolute change (in normalized 0 - 100 scale) ≥ 10 as compared to the baseline. Response rate 95% confidence interval based on normal approximation.
| percentage of participants | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52 | 70.6 (60.9 to 80.3) | 69.3 (59.7 to 79.0) | 71.4 (61.8 to 81.1) | 72.7 (63.4 to 82.0) |
Collected over up to Week 52 (or last dose of study drug) plus 70 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 8/85 (9.4%) | 66/85 (77.6%) |
| ABT-981 25 mg | — | 11/89 (12.4%) | 63/89 (70.8%) |
| ABT-981 100 mg | — | 8/85 (9.4%) | 65/85 (76.5%) |
| ABT-981 200 mg | — | 4/88 (4.5%) | 75/88 (85.2%) |
| Event | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 2/85 | 0/89 | 1/85 | 0/88 |
| ENTEROCOLITISGastrointestinal disorders | 1/85 | 0/89 | 0/85 | 0/88 |
| SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders | 1/85 | 0/89 | 0/85 | 0/88 |
| CHOLECYSTITISHepatobiliary disorders | 0/85 | 1/89 | 1/85 | 0/88 |
| LIVER DISORDERHepatobiliary disorders | 1/85 | 0/89 | 0/85 | 0/88 |
| DIVERTICULITISInfections and infestations | 1/85 | 0/89 | 0/85 | 0/88 |
| PNEUMONIAInfections and infestations | 0/85 | 0/89 | 1/85 | 0/88 |
| URINARY TRACT INFECTIONInfections and infestations | 1/85 | 0/89 | 0/85 | 0/88 |
| ANKLE FRACTUREInjury, poisoning and procedural complications | 1/85 | 1/89 | 0/85 | 0/88 |
| CERVICAL VERTEBRAL FRACTUREInjury, poisoning and procedural complications | 0/85 | 0/89 | 1/85 | 0/88 |
| Event | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg |
|---|---|---|---|---|
| HEADACHENervous system disorders | 22/85 | 14/89 | 14/85 | 21/88 |
| NEUTROPENIABlood and lymphatic system disorders | 1/85 | 12/89 | 12/85 | 21/88 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 16/85 | 16/89 | 19/85 | 14/88 |
| NASOPHARYNGITISInfections and infestations | 16/85 | 9/89 | 13/85 | 17/88 |
| BACK PAINMusculoskeletal and connective tissue disorders | 14/85 | 8/89 | 11/85 | 14/88 |
| NEUTROPHIL COUNT DECREASEDInvestigations | 1/85 | 3/89 | 13/85 | 13/88 |
| FATIGUEGeneral disorders | 12/85 | 4/89 | 5/85 | 7/88 |
| INJECTION SITE REACTIONGeneral disorders | 0/85 | 6/89 | 8/85 | 12/88 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/85 | 8/89 | 7/85 | 12/88 |
| INFLUENZAInfections and infestations | 10/85 | 2/89 | 5/85 | 4/88 |
Modified intent-to-treat population: all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg | Total |
|---|---|---|---|---|---|
| Mean | 59.53 ± 8.850 | 61.63 ± 7.546 | 60.21 ± 8.194 | 59.05 ± 10.273 | 60.11 ± 8.792 |
| Sex: Female, Male(Participants) | Placebo | ABT-981 25 mg | ABT-981 100 mg | ABT-981 200 mg | Total |
|---|---|---|---|---|---|
| Female | 52 | 63 | 53 | 57 | 225 |
| Male | 33 | 26 | 32 | 31 | 122 |
No study locations are listed for this record.
Ran from Jun 2014 to primary completion in Jun 2016, 24 months.
Results were first posted in Aug 2019, 3 years 2 months after primary completion. A results delay was requested in Aug 2017.
Of 58 industry-sponsored phase 2 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 25. This study's 24 months is above that.
Counting every sponsor, half of 101 studies reached it within 20 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lutikizumab